Comparative Pharmacology
Head-to-head clinical analysis: LORTAB versus TYLOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LORTAB versus TYLOX.
LORTAB vs TYLOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is a mu-opioid receptor agonist; acetaminophen inhibits cyclooxygenase (COX) and modulates pain pathways centrally.
Tylox combines oxycodone, a mu-opioid receptor agonist, with acetaminophen, which inhibits cyclooxygenase (COX) and modulates descending serotonergic pathways.
1-2 tablets (each containing 5 mg hydrocodone/325 mg acetaminophen) orally every 4-6 hours as needed for pain. Maximum acetaminophen 3000 mg/day.
1-2 capsules (oxycodone 5 mg/acetaminophen 325 mg) orally every 6 hours as needed for pain; maximum 12 capsules per day.
None Documented
None Documented
Hydrocodone: 3.3-4.4 hours in adults; prolonged in hepatic/renal impairment (up to 6-8 hours). Clinical context: requires 4-6 hour dosing intervals; steady-state in ~24 hours.
Oxycodone: 3.5-5.6 hours; acetaminophen: 2-3 hours. In hepatic impairment, oxycodone half-life prolonged up to 13 hours.
Renal: ~90% (unchanged: ~5% hydrocodone, ~60% hydromorphone and other conjugates; codeine-like metabolites). Biliary/fecal: minor (<10%).
Renal: oxycodone ~19% unchanged; acetaminophen ~2-5% unchanged. Biliary: minimal. Fecal: <5% total. Total renal elimination: ~60-70% as metabolites of oxycodone (noroxycodone, oxymorphone) and acetaminophen conjugates.
Category C
Category C
Opioid analgesic combination
Opioid analgesic combination